prikaz prve stranice dokumenta Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment
  Preuzmi
PDF 152.75 KB
Znanstveni rad - Izvorni znanstveni rad
Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment
HIV Medicine, 21 (2020), 9; 599-606. https://doi.org/10.1111/hiv.12888
Mocroft, A; Neesgard, B; Zangerle, R; Rieger, A; Castagna, A; Spagnuolo, V; Antinori, A; Lampe, FC; Youle, M; Vehreschild, JJ; Mussini, C; Borghi, V; Begovac, Josip; Duvivier, C; Gunthard, HF; Rauch, A; Tiraboschi, J; Chkhartishvili, N; Bolokadze, N; Wit, F; Wasmuth, JC; De Wit, S; Necsoi, C; Pradier, C; Svedhem, V; Stephan, C; Petoumenos, K; Garges, H; Rogatto, F; Peters, L; Ryom, L Više autora...

Citiranost:
,
Citirajte ovaj rad

Mocroft, A., Neesgard, B., Zangerle, R., Rieger, A., Castagna, A., Spagnuolo, V. ... Ryom, L. (2020). Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment. HIV Medicine, 21. (9), 599-606. doi: 10.1111/hiv.12888

Mocroft, A, et al. "Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment." HIV Medicine, vol. 21, br. 9, 2020, str. 599-606. https://doi.org/10.1111/hiv.12888

Mocroft, A, B Neesgard, R Zangerle, A Rieger, A Castagna, V Spagnuolo, A Antinori, et al. "Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment." HIV Medicine 21, br. 9 (2020): 599-606. https://doi.org/10.1111/hiv.12888

Mocroft, A., et al. (2020) 'Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment', HIV Medicine, 21(9), str. 599-606. doi: 10.1111/hiv.12888

Mocroft A, Neesgard B, Zangerle R, Rieger A, Castagna A, Spagnuolo V, i sur.. Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment. HIV Medicine [Internet]. 26.06.2020. [pristupljeno 13.03.2025.];21(9):599-606. doi: 10.1111/hiv.12888

A. Mocroft, et al., "Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment", HIV Medicine, vol. 21, br. 9, str. 599-606, Lipanj 2020. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:601886. [Citirano: 13.03.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:601886
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment
AutorA Mocroft
AutorB Neesgard
AutorR Zangerle
AutorA Rieger
AutorA Castagna
AutorV Spagnuolo
AutorA Antinori
AutorFC Lampe
AutorM Youle
AutorJJ Vehreschild
AutorC Mussini
AutorV Borghi
AutorJosip Begovac
AutorC Duvivier
AutorHF Gunthard
AutorA Rauch
AutorJ Tiraboschi
AutorN Chkhartishvili
AutorN Bolokadze
AutorF Wit
AutorJC Wasmuth
AutorS De Wit
AutorC Necsoi
AutorC Pradier
AutorV Svedhem
AutorC Stephan
AutorK Petoumenos
AutorH Garges
AutorF Rogatto
AutorL Peters
AutorL Ryom
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INFEKTOLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Infektologija
Sažetak (engleski)
Objectives: Although outcomes of antiretroviral therapy (ART) have been evaluated in randomized controlled trials, experiences from subpopulations defined by age, CD4 count or viral load (VL) in heterogeneous real-world settings are limited. ----- Methods: The study design was an international multicohort collaboration. Logistic regression was used to compare virological and immunological outcomes at 12 ± 3 months after starting ART with an integrase strand transfer inhibitor (INSTI),... Više contemporary nonnucleoside reverse transcriptase inhibitor (NNRTI) or boosted protease inhibitor (PI/b) with two nucleos(t)ides after 1 January 2012. The composite treatment outcome (cTO) defined success as VL < 200 HIV-1 RNA copies/mL with no regimen change and no AIDS/death events. Immunological success was defined as a CD4 count > 750 cells/μL or a 33% increase where the baseline CD4 count was ≥ 500 cells/μL. Poisson regression compared clinical failures (AIDS/death ≥ 14 days after starting ART). Interactions between ART class and age, CD4 count, and VL were determined for each endpoint. ----- Results: Of 5198 ART-naïve persons in the International Cohort Consortium of Infectious Diseases (RESPOND), 45.4% started INSTIs, 26.0% PI/b and 28.7% NNRTIs; 880 (17.4%) were aged > 50 years, 2539 (49.4%) had CD4 counts < 350 cells/μL and 1891 (36.8%) had VL > 100 000 copies/mL. Differences in virological and immunological success and clinical failure among ART classes were similar across age groups (≤ 40, 40-50 and > 50 years), CD4 count categories (≤ 350 vs. > 350 cells/μL) and VL categories at ART initiation (≤ 100 000 vs. > 100 000 copies/mL), with all investigated interactions being nonsignificant (P > 0.05). ----- Conclusions: Differences among ART classes in virological, immunological and clinical outcomes in ART-naïve participants were consistent irrespective of age, immune suppression or VL at ART initiation. While confounding by indication cannot be excluded, this provides reassuring evidence that such subpopulations will equally benefit from contemporary ART. Sakrij dio sažetka
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaHIV Medicine
Brojčani podacivol. 21, br. 9, str. 599-606
p-ISSN1464-2662
e-ISSN1468-1293
DOIhttps://doi.org/10.1111/hiv.12888
URN:NBNurn:nbn:hr:105:601886
Datum objave publikacije2020-06-26
URL dokumentahttps://onlinelibrary.wiley.com/doi/10.1111/hiv.12888
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno 4.0 međunarodna (CC BY-NC 4.0)
Datum i vrijeme pohrane2021-03-24 08:54:07
accessibility

closePristupačnostrefresh

Ako želite spremiti trajne postavke, kliknite Spremi, ako ne - vaše će se postavke poništiti kad zatvorite preglednik.